<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00306566</url>
  </required_header>
  <id_info>
    <org_study_id>CYT004-MelQbG10 02</org_study_id>
    <nct_id>NCT00306566</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity of a Melan-A VLP Vaccine in Early Stage Melanoma Patients</brief_title>
  <official_title>A Phase IIa Study to Evaluate Safety, Tolerability, and Immunogenicity of a Melan-A VLP Vaccine in HLA-A2 Positive Patients With Stage II Malignant Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cytos Biotechnology AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cytos Biotechnology AG</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to monitor a specific cellular immune response in melanoma
      patients at an early stage of the disease, that have been vaccinated with a Melan-A VLP
      vaccine.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Malignant Melanoma</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CYT004-MelQbG10</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Able to provide written informed consent

          -  Able and willing to complete all protocol requirements

          -  Age: 18 years and older

          -  Histological confirmed stage II melanoma

          -  HLA-A*0201 haplotype

          -  Expected survival of at least 6 months

          -  ECOG performance status of 0 or 1

          -  Full recovery from surgery

          -  Adequate organ and bone marrow functions

          -  Sexually active males should use adequate contraception throughout the study period
             and 3 months thereafter.

          -  Females of child bearing potential should use adequate contraception throughout the
             study period and 3 months thereafter, that can be oral contraception or a
             double-barrier local contraception (intra-uterine device plus condom or spermicidal
             gel plus condom), and have a negative serum pregnancy test within 4 weeks prior to the
             first dose of the vaccine.

        Exclusion Criteria:

          -  Pregnant or nursing

          -  Use of an investigational drug within 30 days before enrolment

          -  Active malignancy in the 5 years prior to enrollment other than melanoma, basal cell
             carcinoma or cervical carcinoma in situ.

          -  Major surgery within 4 weeks prior to enrollment.

          -  Current use of an immunosuppressive drug or any concomitant medication that could
             potentially interfere with the study drug (e.g. steroids, antihistamine drugs; topical
             or inhalational steroids are permitted).

          -  Presence of significant cardiovascular, renal, pulmonary, endocrine, infectious, or
             neurological disorders.

          -  Serum tests positive for HIV, HBV, HCV.

          -  Active autoimmune diseases or severe allergies.

          -  Current diagnosis or history of relevant and severe psychiatric disorder that
             compromises the patient's ability to understand the patient information, to give
             informed consent, to comply with the trial protocol or to complete the study.

          -  Blood donation or loss of &gt; 500mL within 8 weeks prior to inclusion.

          -  Abuse of alcohol or other recreational drugs.

          -  Previous vaccination with a Melan-A analog peptide.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Danielle Lienard, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Pluridisciplinaire d'Oncologie &amp; LICR, CHUV</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Pluridisciplinaire d'Oncologie &amp; LICR, CHUV</name>
      <address>
        <city>Lausanne</city>
        <state>Vaude</state>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>September 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 23, 2006</study_first_submitted>
  <study_first_submitted_qc>March 23, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 24, 2006</study_first_posted>
  <last_update_submitted>September 19, 2007</last_update_submitted>
  <last_update_submitted_qc>September 19, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 20, 2007</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

